Molecular and Cellular Research in Neurodegenerative Diseases

A special issue of Brain Sciences (ISSN 2076-3425). This special issue belongs to the section "Neurodegenerative Diseases".

Deadline for manuscript submissions: 25 April 2026 | Viewed by 686

Special Issue Editor


E-Mail Website
Guest Editor
1. Department of Biomedical Sciences, School of Health Sciences, International Hellenic University, 5400 Thessaloniki, Greece
2. Laboratory of Medical Biology-Genetics, Faculty of Health Sciences, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece
Interests: genetics; neurodegeneration; Parkinson’s disease; Alzheimer’s disease; biomarkers; pharmacogenetics
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Neurodegenerative diseases (NDs) are characterized by the progressive loss of selectively vulnerable neuronal populations. NDs include a wide range of diseases, including Parkinson’s disease (PD), Alzheimer’s disease (AD), Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS). As the global population ages, the prevalence of NDs is increasing, with major health, social and economic impacts worldwide. Despite significant research efforts, the pathophysiology of NDs still remains elusive.

This Special Issue is focused on the genetic, biochemical, cellular and pathological characteristics of NDs. We are particularly interested in original articles, reviews, case reports and meta-analyses that provide new insights into the molecular and cellular mechanisms associated with NDs, aiming to better understand the pathogenesis of NDs, recognize disease susceptibility and facilitate diagnosis, prediction and therapy in these chronic, debilitating diseases.

Dr. Kallirhoe Kalinderi
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Brain Sciences is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • neurodegenerative diseases
  • Parkinson’s disease
  • Alzheimer’s disease
  • Huntington’s disease
  • amyotrophic lateral sclerosis
  • gene
  • mechanism
  • molecular
  • cellular
  • pathophysiology

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

16 pages, 488 KB  
Article
Plasma Neurofilament Light Chain in Patients Affected by Alzheimer’s Disease with Different Rate of Progression: A Retrospective Study on an ADNI Cohort
by Giuseppe Virga, Bruno Di Marco, Valeria Blandino and Tommaso Piccoli
Brain Sci. 2025, 15(9), 924; https://doi.org/10.3390/brainsci15090924 - 27 Aug 2025
Abstract
Background: Alzheimer’s disease (AD) shows highly variable progression rates among individuals. Plasma neurofilament light chain (NfL) has emerged as a potential biomarker of neurodegeneration. Objectives: this study aimed to evaluate the predictive value of plasma NfL in estimating the rate of clinical progression [...] Read more.
Background: Alzheimer’s disease (AD) shows highly variable progression rates among individuals. Plasma neurofilament light chain (NfL) has emerged as a potential biomarker of neurodegeneration. Objectives: this study aimed to evaluate the predictive value of plasma NfL in estimating the rate of clinical progression (RoP) in AD. Methods: we retrospectively analyzed 87 AD patients from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database. We stratified patients into two groups based on the median RoP, which was calculated from longitudinal Mini-Mental State Examination (MMSE) score evaluations: slow decliners (SD) and fast decliners (FD). We then compared plasma NfL levels between the two groups and examined their relationship with the progression rate. Results: patients with faster decline rates had higher levels of NfL. Logistic regression (LR) analysis revealed a strong correlation between plasma NfL levels and disease progression rates. Furthermore, a multivariate model incorporating Aβ42 levels improved predictive accuracy. Conclusions: these findings suggest that plasma NfL could serve as a valuable biomarker for monitoring the progression of Alzheimer’s disease, identifying patients at greater risk of rapid decline, and optimizing therapeutic strategies and clinical management. Future studies on larger cohorts will be essential to confirm and further explore these observations. Full article
(This article belongs to the Special Issue Molecular and Cellular Research in Neurodegenerative Diseases)
Show Figures

Figure 1

Back to TopTop